Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo Therapeutics (SGMO) reported a Q2 loss of $0.08 per share, missing the Zacks Consensus Estimate of a $0.07 loss, and revenues of $18.31 million, falling short of estimates by 9.38%. This continues a pattern of underperformance, as the company has surpassed consensus EPS and revenue estimates only once in the past four quarters. SGMO shares have significantly underperformed the broader market, declining 48.1% year-to-date, with future price movement largely dependent on management's commentary during the earnings call, despite the stock currently holding a Zacks Rank #3 (Hold).

Analysis

Sangamo Therapeutics (SGMO) reported a disappointing second quarter, missing consensus estimates on both top and bottom lines. The company posted a quarterly loss of $0.08 per share, which was wider than the anticipated $0.07 loss, representing a negative earnings surprise of 14.29%. Similarly, revenues of $18.31 million fell 9.38% short of forecasts. This performance continues a pattern of execution challenges, as SGMO has now surpassed consensus EPS and revenue estimates only once in the last four quarters. While the results show a marked improvement from the prior year's loss of $0.17 per share and revenues of just $0.36 million, this progress is overshadowed by the failure to meet current market expectations. The stock's severe underperformance, a 48.1% decline year-to-date against a 7.9% gain in the S&P 500, reflects investor concern. With a current Zacks Rank of #3 (Hold), the near-term outlook is neutral, and any potential for a reversal will depend heavily on management's commentary and future guidance, especially with consensus estimates pointing to a sequential revenue decline to $7 million in the upcoming quarter.

Key Decisions for Investors

• Given the consecutive misses on both EPS and revenue, investors should view the stock's significant underperformance as a key risk and scrutinize management's upcoming earnings call for a credible path to operational consistency.
• The substantial year-over-year revenue growth is a notable data point, but it is heavily counteracted by forward estimates predicting a sharp sequential decline, warranting caution before establishing or adding to a position based on the top-line figures.
• With a Zacks Rank #3 (Hold) indicating an expectation of in-line market performance, initiating new long positions appears high-risk until there is a clear trend of positive earnings estimate revisions following management's commentary.